Key result
Smoking after heart transplantation is linked to ~54% lower 5-year survival alongside increased vasculopathy and malignancy.
Why the study?
Risk factors for the development of vasculopathy and malignancies after heart transplantation are not well defined.
Does smoking after heart transplantation increase mortality, graft vasculopathy, and cancer in heart transplant recipients?
Cohort (n=84)
Does smoking after heart transplantation increase mortality, graft vasculopathy, and cancer in heart transplant recipients?
Absolute Event Rate: 37% vs 80%
p-value: p=< 0.0001
Smoking after heart transplantation is associated with significantly reduced 5- and 10-year survival, higher rates of transplant vasculopathy, and increased malignancies.
No takes yet. Share an insight, caveat, or question.
May identify age and immunosuppression-related risks after heart transplant; leaves open validation in contemporary cohorts.
Nägele et al. (1997) conducted a cohort in Heart transplantation (n=84). Smoking vs. Non-smokers was evaluated on 5-year survival (p=< 0.0001). Smoking after heart transplantation significantly reduced 5-year survival compared to non-smokers (37% vs 80%, P<0.0001) and increased the prevalence of transplant vasculopathy and malignancies.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: